Nicotinamide riboside for Systolic Heart Failure

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Systolic Heart Failure+2 MoreNicotinamide riboside - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether the dietary supplement nicotinamide riboside (NR) can improve heart function in heart failure patients by increasing levels of the metabolite nicotinamide adenine dinucleotide (NAD+).

Eligible Conditions
  • Heart Failure
  • Metabolic Disorders
  • Systolic Heart Failure
  • Chronic Heart Failure (CHF)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Up to 14 days

Up to 14 days
Between-group comparisons of inflammatory markers in blood
Between-group comparisons of inflammatory markers in myocardium
Between-group comparisons of myocardial NAD(H) levels
Between-group comparisons of myocardial gene expression by RNA-seq and the myocardial epigenome by ATAC-seq
Between-group comparisons of myocardial mitochondrial morphology.
Between-group comparisons of myocardial mitochondrial respiratory function.
Between-group comparisons of myocardial protein acetylation
Between-group comparisons of whole blood NAD+ levels
Correlations of myocardial NAD(H) levels with measures
Correlations of whole blood NAD+ levels with measures

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Nicotinamide riboside
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

40 Total Participants · 2 Treatment Groups

Primary Treatment: Nicotinamide riboside · Has Placebo Group · Phase < 1

Nicotinamide riboside
Drug
Experimental Group · 1 Intervention: Nicotinamide riboside · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 14 days

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,593 Previous Clinical Trials
46,945,806 Total Patients Enrolled
University of WashingtonLead Sponsor
1,597 Previous Clinical Trials
1,569,109 Total Patients Enrolled
Kevin D O'Brien, MDPrincipal InvestigatorUniversity of Washington
2 Previous Clinical Trials
38 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are scheduled for elective LVAD implantation.